The pro-survival Bcl-2 family member Mcl-1 is expressed in chronic lymphocytic leukaemia (CLL), with high expression correlated with progressive disease. The spliceosome inhibitor spliceostatin A (SSA) is known to regulate Mcl-1 and so here we assessed the ability of SSA to elicit apoptosis in CLL. SSA induced apoptosis of CLL cells at low nanomolar concentrations in a dose-and timedependent manner, but independently of SF3B1 mutational status, IGHV status and CD38 or ZAP70 expression. However, normal B and T cells were less sensitive than CLL cells (P = 0.006 and P o 0.001, respectively). SSA altered the splicing of anti-apoptotic MCL-1 L to MCL-1 s in CLL cells coincident with induction of apoptosis. Overexpression studies in Ramos cells suggested that Mcl-1 was important for SSA-induced killing since its expression inversely correlated with apoptosis (P = 0.001). IL4 and CD40L, present in patient lymph nodes, are known to protect tumour cells from apoptosis and significantly inhibited SSA, ABT-263 and ABT-199 induced killing following administration to CLL cells (P = 0.008). However, by combining SSA with the Bcl-2/Bcl-x L antagonists ABT-263 or ABT-199, we were able to overcome this pro-survival effect. We conclude that SSA combined with Bcl-2/Bcl-x L antagonists may have therapeutic utility for CLL.
INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is characterized by the accumulation of neoplastic lymphocytes in peripheral blood, bone marrow, lymph nodes and spleen. It is incurable without allogeneic transplantation and exhibits a high degree of heterogeneity in clinical course. Progressive disease is characterized by unmutated immunoglobulin heavy variable (IGHV) genes, ZAP70 and CD38 expression. 1 Genetic markers including deletions of 17p, 11q and 13q, trisomy 12 and TP53 mutations [2] [3] [4] have been known to impact prognosis for some time, however with the emergence of next-generation sequencing, a plethora of new genetic alterations have been identified including NOTCH1 (10-15%) [5] [6] [7] [8] and SF3B1 (10-17%) [8] [9] [10] mutations that identify patients with progressive disease. 8 SF3B1 is one of the proteins that make up the spliceosome and regulates excision of introns from pre-mRNA. 11 The catalytic core is made up of five small nuclear protein complexes (snRNP), U1, U2, U4, U5 and U6. SF3B1 belongs to the U2 snRNP complex implicated in constitutive and alternative splicing within eukaryotic cells. Mutations in SF3B1 are generally missense mutations, predicted to generate altered splicing function. 8 They elicit changes in the RNA splicing profile in CLL cells and can affect important genes such as FOXP1, ATM and TNIP1 among others. 9, 12 Therefore targeting the spliceosome may be a novel therapeutic approach for the treatment of CLL. Several compounds are available for this purpose, [13] [14] [15] [16] including meayamycin B 17, 18 and the structurally related spliceostatin A (SSA). 16 SSA is a synthetically modified analogue of the natural product FR901464, 19 whereas meayamycin B is prepared by total synthesis. 20 SSA binds to SF3B1 and possibly other members of the splicing factor 3 complex and targets normal splicing in the cell, promoting alternative gene splicing, accumulation of unspliced mRNAs in the nucleus and a decrease in translation. 16 Numerous transcripts have been shown to be downmodulated by SSA-altered splicing in HeLa cells. 21 Furthermore, work in neuroblastoma cells has highlighted the importance of the spliceosome in regulating the expression of the pro-survival Bcl-2 family member Mcl-1. 22 In CLL, Mcl-1 expression correlates with stage of disease, lymphocyte doubling time, IGHV mutation status, ZAP70 positivity and CD38 expression. 23 Furthermore, the Mcl-1 expression level and the Mcl-1/Bax ratio correlate with resistance to fludarabine and time to first treatment. 23 Mcl-1 may also be expressed to a greater extent in CLL lymph nodes compared with blood, where resistance to apoptosis is known to occur. 24 The emergence of Bcl-2 inhibitors such as ABT-263 and ABT-199 are showing considerable promise for the treatment of CLL; however, these drugs are unable to inhibit the anti-apoptotic effects of Mcl-1 conferred by the microenvironment, 25 thus identifying a known mechanism of resistance to these BH3 mimetics. [26] [27] [28] [29] Several pan-Bcl-2 family inhibitors such as obatoclax, sabutoclax and AT-101 have been developed with low micromolar potency against Mcl-1. Obatoclax (a BH3 mimetic) has been investigated in a phase I clinical trial for advanced CLL, but its effect was limited. 30 Studies on AT-101 with rituximab showed some efficacy, resulting in partial remissions. 31, 32 Therefore, there is a need to develop alternative Mcl-1 inhibitors perhaps in combination with Bcl-2/Bcl-x L inhibitors.
In this study, we showed that the SF3B1 splicing inhibitor SSA induced robust apoptosis in CLL cells while normal lymphocytes were significantly more resistant. Apoptosis was induced independently of SF3B1 mutation status. SSA-induced apoptosis correlated with altered MCL-1 RNA splicing and downregulation in Mcl-1 L protein expression. IL4 and CD40L treatment conferred resistance to SSA-induced apoptosis; however, this resistance was reversed by combining SSA with the Bcl-2 family inhibitors ABT-199 or ABT-263. These data suggest that microenvironmental signals in the lymph node may make the CLL cells that reside there resistant to SSA. Therefore, combining inhibitors of both Bcl-2/Bcl-x L and Mcl-1 may be warranted for the treatment of CLL.
MATERIALS AND METHODS Patients
Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria. 3 Fifty-nine samples were obtained from patients diagnosed with CLL at the Royal Bournemouth Hospital and Southampton General Hospital following ethical committee approvals (06/Q2202/30 and 228/02/t, respectively) under the declaration of Helsinki (Supplementary Table 1 ). Malignant cell isolation and the determination of their purity have been described previously. 33 Isolates typically contained 490% CD19 + CD5 + cells. Normal B and T lymphocytes from peripheral blood were taken from healthy agematched controls as previously described. 34 Mutational screening for SF3B1 was carried out by Sanger sequencing as previously reported (Supplementary Table 2 ). 8 
Reagents and antibodies
Spliceostatin A was produced by Professor Yoshida (Riken Institute, Wako, Japan). 16 Meayamycin B was produced by the Koide group (University of Pittsburgh, Pittsburgh, PA, USA). 20 ABT-199 and ABT-263 were purchased from Selleckchem (Boston, MA, USA). Annexin V-FITC was produced inhouse (Southampton CR-UK core protein production facility). Pan-caspase inhibitor Z-VAD.fmk (Z-VAD) was from Enzo Life Sciences (Exeter, UK) and Q-VD-OPh was from Calbiochem (Watford, UK). Recombinant human IL4 and CD40L were from R&D Systems (Abingdon, UK). Antibodies for flow cytometry and immunoblotting are detailed in Supplementary Table 3. Cell culture CLL cells were cultured as previously described. 35 The Burkitt's lymphoma cell lines Ramos and Raji were obtained from ECACC (Salisbury, UK). Cells were maintained in RPMI-1640 supplemented with 10% FCS, 2 mM glutamine, penicillin/streptomycin and 1 mM sodium pyruvate (Life Technologies, Paisley, Scotland).
Cell viability assay
Cell death was measured by flow cytometry of Annexin V-FITC and propidium iodide (PI) labelled cells as previously described. 36 Viable cells were negative for both Annexin V and PI. Fifty percent inhibitory concentration values (IC 50 ) were measured using CalcuSyn software (Biosoft, Cambridge, UK). The combination effect of SSA and ABT-199 or ABT-263 was calculated by comparing the expected and observed survival, as previously described for CLL. 37, 38 RT-PCR Total RNA was isolated with the RNeasy mini kit (Qiagen, Manchester, UK) as described by the manufacturer. Total RNA was reverse-transcribed with M-MLV enzyme (Promega, Southampton, UK). Conventional PCR was performed for DNAJB1, RIOK3, MCL-1, BCL-X and UBIQUITIN (Supplementary  Table 3 ) using the GoTaq Green Master Mix (Promega). Real-time PCR was performed on a LightCycler 480 (Roche, Welwyn Garden City, UK) using Syto9 (Life Technologies). Each sample was analysed in triplicate with UBIQUITIN as a house-keeping control. The relative gene expression was calculated by the 2 − ΔΔCT method. Each sample was normalized to its nontreated matched sample.
Immunoblotting
Immunoblot analysis was performed as previously described. 36 Proteins were separated on 12% polyacrylamide gels (Life Technologies). Blots were probed with primary antibodies (Supplementary Table 2 ) and secondary antibodies (Dako, Ely, UK). Blots were visualized with ChemiDoc-It Imaging System (UVP, Cambridge, UK) and densitometry performed with Image J (NIH, Bethesda, MD, USA).
Nucleofection
Nucleofection was performed with the Amaxa Cell Line Nucleofector Kit V (Lonza, Cambridge, UK), according to the manufacturer's instructions. Cells were nucleofected with the empty vector pcDNA3 (mock) or pcDNA3-9E10-Mcl-1 L plasmid, and were selected in complete media with 1 mg/ml geneticin (Life Technologies). Clones were evaluated for Mcl-1 L overexpression after 14 days.
Statistical analysis
The normal distribution of the samples was tested by D'Agostino-Pearson test. Statistical differences between groups were evaluated by the Student's t-test or ANOVA when samples were normally distributed or by the Mann − Whitney U or Kruskal-Wallis test when samples were not. Correlation analysis was carried out using Pearson or Spearman test depending on the normality of the samples. Statistical analysis was performed using GraphPad Prism v6 (GraphPad Software Inc., La Jolla, CA, USA). Figures 1A and B) significantly protected against SSA-induced cell death even at the highest concentrations (P = 0.0027 and P = 0.034 at 10 and 20 nM, respectively). Moreover, SSA induced substantial apoptosis within 12-24 h in a dose-dependent manner (Figure 1d ). Sensitivity to SSA is independent of SF3B1 mutational status Due to the incidence of SF3B1 mutations in CLL, 8, 10 we compared the effect of SSA on 13 patients carrying a mutation in this gene and 42 wild-type patients. The SF3B1 mutations observed reflected the spectrum reported previously (Supplementary Table 2 ). 8 We confirmed that the splicing of ATM, FOXP1 and TNIP1 was altered in these samples as previously described (Supplementary Figures  2A and C) . 9, 12 However, no significant difference between the mean SSA IC 50 of wild-type (5.5 nM) and SF3B1-mutated samples (4.9 nM; P = 0.516) was observed ( Figure 2a ). In addition, SSA appears equally effective at inducing substantial apoptosis independently of IGHV mutational status, ZAP70 or CD38 expression, and genetic abnormalities [del(13q), Tri12, del(11q) and del (17p) SSA induces changes in MCL-1 splicing To assess the effect of SSA on splicing within CLL cells, we studied the genes DNAJB1 and RIOK3 in which other splicing inhibitors have been shown to induce intron retention (larger RT-PCR products). SSA induced a dose-dependent increase in the unprocessed mRNA species compared with the mature mRNA ( Figure 3a ). Therefore, SSA was shown to decrease the capability of the CLL cells to correctly process pre-mRNAs. The siRNAmediated knockdown of SF3B1 induces changes in the splicing of MCL-1 and BCL-X in solid tumours, 39 so we investigated the effect of SSA on MCL-1 and BCL-X in CLL cells. SSA decreased MCL-1 L and increased MCL-1 s isoforms in a dose-dependent manner even in the presence of Z-VAD (Figure 3b ), confirming that the accumulation of MCL-1 s was not an indirect result of caspase cleavage and cell destruction. In contrast, BCL-X showed no altered splicing following SSA treatment (Figure 3c ). SSA-induced altered splicing of MCL-1 occurred in a time-and dose-dependent manner (Figures 3d-f ), occurring as early as 6 h after 5 nM SSA administration and immediately before CLL apoptosis. Importantly, MCL-1 splicing occurred to the same extent in both wild-type and SF3B1-mutated samples (Supplementary Figures 4A and B) . In addition, the changes in MCL-1 splicing were specific to SSA, as other drugs used to treat CLL did not affect this gene (Supplementary Figure 4C) . (Figures 5a and b) , in a dose-, time-and caspasedependent manner (Figures 5b and c) . We also showed that SSA downregulated Mcl-1 L expression in Ramos cells, akin to that in CLL (Figure 5a ). We then nucleofected Ramos cells with plasmids containing a Myc-tagged Mcl-1 L protein or the empty plasmid (mock) and selected three stable clones, which overexpressed Myc-tagged Mcl-1 L that is unable to be alternatively spliced by SSA (Figure 5d ). Importantly, these clones were selected to reflect levels of ectopic Mcl-1 L that could be considered physiological. (Figure 6b ). However, SSA was still able to promote MCL-1 splicing (Figure 6c ). These data again suggest that increased Bcl-x L expression by IL4/CD40L is associated with resistance to SSA. Figures 7A and B) . However, any combination effects were difficult to discern due to the substantial amount of apoptosis with the compounds alone (Supplementary Figure 7B) . In contrast, following IL4/CD40L stimulation, CLL cells underwent significantly less SSA-and ABT-199-induced cell death, while becoming completely resistant to ABT-263 (Figure 7b) . Nevertheless, the combination of SSA with ABT-263 or ABT-199 significantly augmented CLL apoptosis (Figures 7a and b) . Using the fractional two-drug analysis method previously described for CLL, 38, 44 we evaluated the synergistic interaction between SSA and ABT compounds. Values above the diagonal line represent additive interaction while those under the line are synergistic. Under basal conditions, the drug combinations presented additive or synergistic effects in most of the patients (Supplementary Figures 7C and D) . In the presence of IL4/CD40L, a strong synergistic relationship was observed following treatment with SSA and ABT-199 (Figure 7c ) or ABT-263 (Figure 7d ). It was noteworthy that the combination of SSA and ABT-199 or ABT-263 also presented marked synergistic effects on 17p deleted samples after IL4/CD40L stimulation (Supplementary Figure 8) . These data suggest that SSA in combination with Bcl-2/Bcl-x L inhibitors may be a useful strategy for targeting cells receiving microenvironmental signals within the protective lymph-node niche. apoptosis. 45, 46 While compounds have been developed to mimic BH3 proteins, many of these target Bcl-2, Bcl-x L and Bcl-w with little to no effect on Mcl-1. 45, 47 It is known that targeting all prosurvival members is critical for efficient apoptosis 48 and CLL is known to have elevated levels of Bcl-2, Bcl-x L and Mcl-1 in lymph nodes. 24 Furthermore, Mcl-1 expression is known to correlate with progressive disease, resistance to chemotherapy and time to first treatment, 23 therefore overcoming Mcl-1 is likely to be critical for effectively treating CLL.
RESULTS

SSA
In this study, SSA, an analogue of FR901464 that inhibits the SF3B1 protein, induced altered splicing and downregulation of Mcl-1 L , which was concordant with caspase-dependent apoptosis of CLL cells at low nanomolar concentrations. In agreement with the key role of Mcl-1 in regulating CLL survival, we saw an inverse correlation between Mcl-1 L expression and sensitivity to SSA in CLL samples. Interestingly, 2-and 14-fold higher concentrations of SSA were required to kill normal B and T cells, respectively. This sensitivity profile indicates that B cells and particularly tumour B cells are more sensitive to spliceosome interference than T cells. The molecular basis behind this is unclear but since Mcl-1 and Bcl-x L are essential for T-cell survival, 49 resistance may relate to Bcl-x L overexpression or differential splicing by SSA in B and T cells.
SSA-induced killing of CLL cells was independent of the mutational status of SF3B1 and IGHV, as well as, CD38 and ZAP70 expression. SF3B1 mutations have been shown to be present at sub-clonal levels; 50 however, all our SF3B1 mutant samples exhibited deregulated splicing supporting the notion that the SF3B1 mutant protein in these cases has a functional impact. The equal sensitivity of CLL samples to SSA indicates a common mechanism of cell death irrespective of the size of the SF3B1-mutated clone within the population. Therefore, further correlations between SSA sensitivity and SF3B1 mutant sub-clonal levels from deep-sequencing data will be required to fully elucidate this relationship and these studies are ongoing. Furthermore, we showed that SF3B1-mutated samples have a significantly greater IC 50 for chlorambucil than WT samples. These data suggest that SF3B1 mutations may confer reduced sensitivity to drug-induced apoptosis supporting previous reports with fludarabine.
51
The binding of SSA to SF3B1 inhibits pre-RNA splicing 16 but also induces changes in alternative splicing. 52 We have demonstrated in CLL cells that SSA promotes alternative splicing of MCL-1. Laetsch et al. 22 observed similar results in neuroblastoma cell lines. A reduction of SF3B1 protein by siRNA in HeLa cells resulted in a similar increase in the MCL-1 S :MCL-1 L ratio; 39 however, in neuroblastoma cell lines SF3B1 knockdown increased the production of MCL-1 L modestly and MCL-1 S markedly. 22 Together, these data hint to a complex regulation of MCL-1, which likely varies in a cell-and context-dependent manner. In resting CLL cells, MCL-1 L is the main isoform produced by alternative splicing. After SSA treatment, RT-PCR analysis indicated a preferential alternative splicing towards the MCL-1 S isoform, which resulted in a downregulation of the anti-apoptotic Mcl-1 L protein. Previous studies have indicated that Mcl-1 S might have pro-rather than anti-apoptotic properties. 53 We saw no evidence for the generation of mature Mcl-1 S protein before or after SSA treatment in CLL or Ramos cells even in the presence of Z-VAD, suggesting that the Mcl-1 s form is not stable and/or biologically functional in these cells. Supporting our hypothesis that Mcl-1 L reduction is the primary reason for the apoptosis induced by SSA, we saw tight correlation between the reduction in MCL-1 L transcripts, protein expression and apoptosis. Furthermore, overexpression of unspliceable Mcl-1 L in Ramos cells partially protected from SSAinduced apoptosis. This incomplete protection may be due to the fact that SSA also downregulated Bcl-x L , in Ramos cells (but not in CLL or Raji cells). Bcl-x L is not highly expressed in CLL cells in the blood, but is significantly expressed at higher levels in the lymph nodes. 24 In addition, our current observations using IL4/CD40L to mimic this microenvironment suggest that SSA alone may be less effective at treating CLL cells in the lymph-node niche. These data are supported by results with Raji cells, which retained Bcl-x L expression and were relatively insensitive to SSA-induced apoptosis, although Mcl-1 was spliced and downregulated. Another FR901464 analogue, meayamycin B, induced the same reduction on Mcl-1 L expression (this study) and non-small cell lung cancer and head and neck cancer cell lines. 18, 54 Although differential and off-target effects cannot be ruled out completely, the similar responses with two structurally different compounds suggest that cell death is regulated by altered MCL-1 splicing.
In our study, IL4/CD40L stimulation increased the expression of Bcl-x L and Mcl-1 L and reduced the sensitivity of CLL cells to SSA. One explanation for this is that the induction of anti-apoptotic proteins was higher in IL4/CD40L-stimulated cells, indeed the levels of Bcl-x L appeared higher with IL4/CD40L treatment compared with the control. Several Bcl-2 inhibitors have been developed in the last 20 years, including the series of BH3 mimetics pioneered by Abbot. 55 ABT-737, ABT-263 and ABT-199 reflect the best-developed exponents of this approach and have shown promising results as single agents or in combination with other cytotoxic agents. 56 The clinical trial of ABT-263 in CLL demonstrated rapid and profound reduction of CLL cells in the blood, while bone marrow biopsies showed evidence of residual CLL cells. 26 In that study, resistance to ABT-263 correlated with higher Mcl-1 expression levels. 26 However, another study demonstrated that the resistance of CLL cells to ABT-737 was due to Bcl-2A1 and not Mcl-1 expression. 29, 57 Under IL4/CD40L stimulation, ABT-199 or ABT-263 alone failed to induce significant apoptosis in CLL cells, while its combination with SSA produced a dramatic reduction in cell viability. Combinations of the B cell receptor kinase inhibitors (ibrutinib or idelalisib) with Bcl-2 family inhibitors (ABT-199) have been proposed, as ibrutinib and idelalisib cause an efflux of CLL cells out of the lymph nodes into the blood where they can be readily killed by ABT-199. 25 However, patients treated with B cell receptor kinase inhibitors alone still have residual disease in their nodes. We therefore propose that a combination of ABT-199 with SSA may be a more successful approach for targeting residual disease in the lymph nodes in order to provide complete and durable responses for this currently incurable disease. While costs preclude our investigation of SSA and ABT-199 or ABT-263 either alone or in combination in vivo, previous studies have been performed with meayamycin B and FR901464 alone and shown some antitumor effect in vivo, further suggesting their promise for use as effective new therapies. 
